Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|March 24, 2009
Three-dimensional in vitro anglogenesis in the rat aortic ring modelDavid C West, Mike F BurbridgeMolecular Pharmacology|May 23, 2003
Decrease in survival threshold of quiescent colon carcinoma cells in the presence of a small molecule integrin antagonistMike F Burbridge, Virginie Venot, Patrick J Casara, et al.Molecular Cancer Therapeutics|June 17, 2017
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of RadiotherapyCéline Clémenson, Cyrus Chargari, Winchygn Liu, et al.Neoplasia (New York, N.Y.)|December 19, 2016
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer ModelsFederica Guffanti, Rosaria Chilà, Ezia Bello, et al.Science Signaling|December 10, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.Science Signaling|December 31, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.Molecular Cancer Therapeutics|June 28, 2013
S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumabMike F Burbridge, Céline J Bossard, Carine Saunier, et al.Pageof 1